Fractyl Health, Inc.
GUTSHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, Fractyl Health, Inc. (GUTS) is listed under Biotechnology. At a $122.3M market cap, Fractyl Health, Inc. ranks as a micro-cap company within healthcare. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Market Cap
$122.3M
Beta
2.29
P/E (TTM)
—
P/E (Fwd)
-1.60
EPS (TTM)
$-1.29
EPS (Fwd)
$-0.48
ROE
-778.3%
ROA
-63.6%
Cash
$63.2M
Total Debt
$60.8M
Free CF
-$50.6M
52W Change
-58.6%
Annual Financials
Cash vs Debt
Where GUTS stands vs its 150-day and 200-day moving averages
As of the June 30, 2026 close, GUTS finished 23.08% below its 150-day moving average ($1.04) and 26.61% below its 200-day moving average ($1.09). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GUTS overbought or oversold?
At the June 30, 2026 close, GUTS's RSI(14) was 60.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Fractyl Health, Inc. holds $63.2M in cash against $60.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$50.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -778.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.29 means GUTS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Fractyl Health, Inc. and its sector.